Evolve BioSystems, Inc. v. Abbott Laboratories

CourtDistrict Court, N.D. Illinois
DecidedDecember 17, 2020
Docket1:19-cv-05859
StatusUnknown

This text of Evolve BioSystems, Inc. v. Abbott Laboratories (Evolve BioSystems, Inc. v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Evolve BioSystems, Inc. v. Abbott Laboratories, (N.D. Ill. 2020).

Opinion

UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

EVOLVE BIOSYSTEMS, INC., ET AL.,

Plaintiffs, No. 19 CV 5859 v. District Judge Lee ABBOTT LABORATORIES, INC., Magistrate Judge McShain Defendant.

MEMORANDUM OPINION AND ORDER

Pending before the Court is a motion filed by plaintiffs Evolve Biosystems, Inc., and the Regents of the University of California to compel defendant Abbott Laboratories to produce a patent list that Abbott has withheld on the basis of the attorney-client privilege. [113].1 Plaintiffs also seek an order compelling Abbott to supplement its response to plaintiffs’ Interrogatory No. 17. The motion is fully briefed [128, 138], and the Court has conducted an in-camera review of the patent list [155, 157]. For the following reasons, the motion is granted in part and denied in part.

Background

As the Court explained in its order resolving plaintiffs’ first motion to compel [112], this patent-infringement suit arises out of the parties’ failed plans to co- promote Evolve’s EVIVO® probiotic product, which is used in neonatal intensive care units, alongside Abbott’s Similac® line of infant care products. Evolve and Abbott entered into discussions about the co-promotion opportunity in 2018. Albert Ihochi, Abbott’s former Director of Venture Partnerships and IP for its Nutrition Research and Development Group, led the evaluation opportunity. [91-1] 1-2, ¶ 3. In the spring of 2019, Ihochi approached Abbott’s Senior Counsel for Patents, Mark Engle, and asked him to “review Evolve’s patent portfolio for the purposes of [Ihochi’s] evaluation

1 Bracketed numbers refer to entries on the district court docket. Referenced page numbers are taken from the CM/ECF header placed at the top of filings. The Court has found it necessary to refer to several sealed filings that the parties have designated “highly confidential,” but the Court has attempted to do so without revealing any information that could be reasonably deemed confidential. To the extent the Court has discussed confidential information, however, the Court has done so because it is necessary to explain the path of its reasoning. See In re Specht, 622 F.3d 697, 701 (7th Cir. 2010); Union Oil Co. of Cal. v. Leavell, 220 F.3d 562, 568 (7th Cir. 2000). of the Evolve opportunity.” [Id.] 2, ¶ 4. Engle “orally discussed with Mr. Ihochi in confidence [his] initial analysis of Evolve’s patent portfolio based on [his] legal knowledge and training of patent law.” [Id.].

Engle also sent Ihochi “the results of a patent search that [he] had conducted” [id.], and it is this document that plaintiffs target in their motion to compel. [Id.]. According to Abbott’s Second Privilege Log, the results of Engle’s search are contained in an Excel spreadsheet that Engle prepared and emailed to Ihochi on May 2, 2019. [114-1] 6. Abbott has withheld the spreadsheet on the ground that it “convey[s] confidential legal advice regarding patent analysis[.]” Id.

Legal Standard

“In patent cases, Federal Circuit law governs privilege disputes that relate to an issue of substantive patent law; otherwise, Seventh Circuit law applies.” RTC Indus., Inc. v. Fasteners for Retail, Inc., Case No. 17 C 3595, 2020 WL 1433828, *1 (N.D. Ill. Mar. 24, 2020) (citing Regeneron Pharms., Inc. v. Merus N.V., 864 F.3d 1343, 1363 n.6 (Fed. Cir. 2017)). Because this dispute does not appear to implicate substantive patent law, and because the parties do not cite any Federal Circuit law, the Court applies Seventh Circuit law.

“The attorney-client privilege protects communications made in confidence by a client and a client’s employees to an attorney, acting as an attorney, for the purpose of obtaining legal advice.” Sandra T.E. v. S. Berwyn Sch. Dist. 100, 600 F.3d 612, 618 (7th Cir. 2010). “The privilege applies to communications both by a client to a lawyer and from a lawyer to a client.” Allendale Mut. Ins. Co. v. Bull Data Sys., Inc., 152 F.R.D. 132, 137 (N.D. Ill. 1993). The Seventh Circuit has summarized “the essential general principles governing the privilege” as follows:

(1) Where legal advice of any kind is sought (2) from a professional legal adviser in his capacity as such, (3) the communications relating to that purpose, (4) made in confidence (5) by the client, (6) are at his instance permanently protected (7) from disclosure by himself or by the legal adviser, (8) except the protection be waived.

United States v. Evans, 113 F.3d 1457, 1461 (7th Cir. 1997).

“The attorney-client privilege applies only if [the communications] constitute legal advice or tend directly or indirectly to reveal the substance of a client confidence.” In re Dealer Mgmt. Sys. Antitrust Litig., 335 F.R.D. 510, 514 (N.D. Ill. 2020) (internal quotation marks omitted). “Many cases note that facts are not protected by attorney-client privilege; in other words, the underlying facts communicated between an attorney and a client can be discovered through depositions or other discovery techniques.” Toyo Tire & Rubber Co., Ltd. v. Atturo Tire Corp., Case No. 14 C 206, 2016 WL 3125004, at *2 (N.D. Ill. June 3, 2016). “[F]acts do ‘not become privileged just because they are communicated to or by a lawyer.’” Baxter Int’l, Inc. v. Becton, Dickinson & Co., Case No. 17 C 7576, 2019 WL 3408813, at *4 (N.D. Ill. July 26, 2019) (quoting Intervet, Inc. v. Merial Ltd., 256 F.R.D. 229, 232-33 (D.D.C. 2009)).

“The party seeking to invoke the privilege bears the burden of proving all of its essential elements.” Id. “Rule 26 mandates that a withholding party make a claim of privilege expressly and ‘describe the nature of the documents, communications, or tangible things not produced or disclosed . . . in a manner that, without revealing information itself privileged or protected, will enable other parties to assess the claim.’” DeLeon v. Reyes-Guevara, Case No. 1:18-cv-01028, 2020 WL 3050230, *3 (N.D. Ill. June 8, 2020) (quoting Fed. R. Civ. P. 26(b)(5)(A)).

“[B]ecause the privilege is in derogation of the search for truth, it is construed narrowly.” Evans, 113 F.3d at 1461.

Discussion

A. Patent List

Plaintiffs argue that the attorney-client privilege does not protect the patent list because the list “contains solely factual information.” [114] 2. Plaintiffs contend that the list is relevant to show when Abbott first learned of Evolve’s patents, and that case law recognizes that “‘the circumstances surrounding an accused infringer’s discovery of a patent are not in themselves protected by the attorney-client privilege.’” [Id.] 4 (quoting Baxter, 2019 WL 3408813, at *3). While plaintiffs acknowledge that the list was prepared by an attorney, they maintain that “circumstances regarding an accused infringer’s knowledge of a patent-in-suit are not privileged ‘even if [the] accused infringer first becomes aware of a patent through its attorney.’” Id. (quoting Baxter, 2019 WL 3408813, at *4).

Abbott responds that Engle’s patent search constitutes “privileged legal analysis and advice.” [128] 5. This is so, Abbott argues, because Engle “relied on confidential information about Abbott’s business strategy to craft a patent search based on his legal assessment of the proper search parameters and strings.” [Id.] 5- 6.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sandra T.E. v. South Berwyn School District 100
600 F.3d 612 (Seventh Circuit, 2010)
In Re Specht
622 F.3d 697 (Seventh Circuit, 2010)
United States v. Jesse J. Evans
113 F.3d 1457 (Seventh Circuit, 1997)
In Re Spalding Sports Worldwide, Inc.
203 F.3d 800 (Federal Circuit, 2000)
Union Oil Company of California v. Dan Leavell
220 F.3d 562 (Seventh Circuit, 2000)
Regeneron Pharmaceuticals, Inc. v. Merus N.V.
864 F.3d 1343 (Federal Circuit, 2017)
Intervet, Inc. v. Merial Ltd.
256 F.R.D. 229 (D.C. Circuit, 2009)
Comair Rotron, Inc. v. Minebea Co.
143 F.R.D. 494 (S.D. New York, 1992)
Burroughs Wellcome Co. v. Barr Laboratories, Inc.
143 F.R.D. 611 (E.D. North Carolina, 1992)
Hydraflow, Inc. v. Enidine Inc.
145 F.R.D. 626 (W.D. New York, 1993)
Allendale Mutual Insurance v. Bull Data Systems, Inc.
152 F.R.D. 132 (N.D. Illinois, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
Evolve BioSystems, Inc. v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/evolve-biosystems-inc-v-abbott-laboratories-ilnd-2020.